期刊档案 · 医学-肿瘤学
Technology in Cancer Research & Treatment
ISSN 1533-0346 · eISSN 1533-0338 · SAGE Publications Inc. · UNITED STATES · Bimonthly · 创刊 2002
Technology in Cancer Research & Treatment 中科院 医学 4区（2025 年升级版），影响因子 2.79，完全开放获取，APC 约 2,650 美元，投稿社区反馈审稿约 2 个月，录用比例约80%（社区反馈），2025 年发文 163 篇，SCIE、Scopus 收录。
研究范围
研究范围与定位
Technology in Cancer Research & Treatment 由 SAGE Publications Inc. 出版，属中科院医学大类（2025 升级版4区）。按 OpenAlex 近年发文统计，该刊主要发表 Advanced Radiotherapy Techniques、Radiation Therapy and Dosimetry、MicroRNA in disease regulation 等主题的论文，这 3 个主题约占 28.4%。（根据 OpenAlex 主题统计与中科院分区数据生成）
Journal HighlightsImpact Factor: 2.8Indexed In: Clarivate Analytics: Social Science Index Expanded (SCIE), PubMed Central (PMC), PubMed: MEDLINE, Scopus, EMBASE, Index Medicus, and the Directory of Open Access Journals (DOAJ)Fast and double-anonymized peer review by dedicated Associate Editors and Editorial Board MembersGlobal visibility due to international audience of multidisciplinary researchersPublication is subject to payment of an article processing charge (APC)Submit hereTechnology in Cancer Research and Treatment (TCRT) is an open access, peer-reviewed journal which focuses on developments in the detection, diagnosis, prognosis and treatment of cancer. Please see the Aims and Scope tab for further information.This journal is a member of the Committee on Publication Ethics (COPE).Submission InformationSubmit your manuscript at https://mc.manuscriptcentral.com/tcrt. Please see the Submission Guidelines tab for more information on how to submit your article to the journal.Open access article processing charge (APC) informationPublication in the journal is subject to payment of an article processing charge (APC). The APC serves to support the journal and ensures that articles are freely accessible online in perpetuity under a Creative Commons license.The article processing charge (APC) for this journal is currently $3200 (+VAT where applicable); Brief Report APCs are $2560, Commentaries are $2560, Original Article (Technical Edit) and Research Article (Technical Edit) are $4200 and Technical Note APCs are $2560.The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here. In some cases, manuscripts may be eligible for a discount or waiver. Please see further details here.ContactPlease direct any peer review-related queries to tct@sagepub.com. All other queries can be sent to TCRTeditor@sagepub.com.Why Publish Open Access with TCRTVisibility and Impact: Anyone anywhere in the world can read, use and cite your researchRigorous Standards: Double-anonymized peer review policySpeed: Less than 2 months from submission to first decision and 4 weeks from acceptance to online publicationFlexibility: No page limits or page charges, and authors can publish full data sets, figures, tables, etcCopyright: Authors retain copyright under a Creative Commons LicenseUseful LinksSubmission PageSubmission Guidelines (PDF)SAGE Open Access Main PageSAGE Open Access FAQsContact the Editor: Applonia.Rose@sagepub.co.ukOther information This journal changed its publication mode from subscription to open access in 2016.
摘自期刊官网 Aims & Scope
研究方向（LetPub）：医学-肿瘤学
编委会国家分布：中国大陆 103 位（约 18%）；主要国家 美国 208、中国 103、意大利 46、印度 29、土耳其 26（共 574 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Advanced Radiotherapy TechniquesPhysics and Astronomy16.6%
- Radiation Therapy and DosimetryMedicine6%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology5.9%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology5.7%
- Medical Imaging Techniques and ApplicationsMedicine5.7%
- Radiomics and Machine Learning in Medical ImagingMedicine5.5%
- Lung Cancer Diagnosis and TreatmentMedicine4.9%
- Circular RNAs in diseasesBiochemistry, Genetics and Molecular Biology4.6%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 肿瘤学ONCOLOGY | 4 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 3 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 3 区 |
| 小类 | 肿瘤学ONCOLOGY | 4 区 |
Top 期刊：否综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 肿瘤学ONCOLOGY | 4 区 |
Top 期刊：否综述期刊：否
数据库收录
SCIEScopusDOAJLetPub
国际期刊预警名单：各版本均未列入LetPub
期刊官网自述收录
Web of ScienceMEDLINEPubMed出版商官网
期刊官网列出的收录清单，未与各数据库逐一核对；Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子
- 2.79LetPub ·
- 影响因子（出版商公布）
- 2.7出版商官网 ·
- 五年影响因子（出版商公布）
- 2.7出版商官网 ·
- CiteScore 2026-06
- 5.2LetPub ·
- SJR 2026-06
- 0.67LetPub ·
- SNIP 2026-06
- 0.75LetPub ·
- h-index
- 56LetPub ·
- h-index
- 86OpenAlex ·
- i10-index
- 1,636OpenAlex ·
- 两年平均被引
- 3.14OpenAlex ·
- 自引率
- 0%LetPub ·
- Gold OA 文章占比
- 99.82%LetPub ·
发文规模
- 年文章数
- 144LetPub ·
- 年发文量（出版商公布）
- 3出版商官网 ·
逐年发文量 OpenAlex 统计 · 累计 3,183 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 162 | 162 | 61 |
| 2025 | 163 | 163 | 440 |
| 2024 | 216 | 216 | 1,196 |
| 2023 | 239 | 239 | 2,267 |
| 2022 | 239 | 239 | 2,699 |
| 2021 | 303 | 303 | 4,247 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
- 平均审稿速度（社区反馈）
- 平均2月LetPub ·
- 平均录用比例（社区反馈）
- 80%LetPub ·
- 录用率（出版商公布）
- 19.8%出版商官网 ·
- 投稿到首次决定
- 6 天出版商官网 ·
- 接收到发表
- 21 天出版商官网 ·
- 投稿到发表（期刊自报）
- 约 13 周DOAJ ·
- 评审方式
- 双盲同行评审DOAJ
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
完全开放获取DOAJ
所有文章开放获取，通常向作者收取文章处理费（APC）。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | USD 2,650 | 有 | CC BY、CC BY-NC | |
| OpenAlex | USD 2,650 | — | — | |
| 出版商官网 | USD 3,200 | — | — |
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点8 项，摘自作者指南
- 摘要
- ≤ 300 词
- 参考文献格式
- AMA 格式
- 稿件模板
- 提供 LaTeX 与 Word 模板
- 首次投稿格式
- 允许不按期刊格式排版（free format）
- 推荐审稿人
- 可选
- Highlights（研究亮点）
- 可选
- 图文摘要
- 可选
- 投稿信（Cover letter）
- 必须提供
接收的文章类型10 种，含篇幅限制
- case studyView our topical sections currently accepting submissions View our Special Collections currently accepting submissions View our Author Resource page for guidanc…未说明篇幅
- commentarychanges or trends related to the field. Commentaries must be less than 2,500 words and have no more than 20 references. Abstract structure: Un正文 ≤ 2,500 词
- editorialesearch and therapy. The word limit for editorial articles is maximum 2,000 words and up to 20 references. In the context of a Special Collec正文 ≤ 2,000 词
- literature reviewView our topical sections currently accepting submissions View our Special Collections currently accepting submissions View our Author Resource page for guidanc…未说明篇幅
- mini reviewnges and potential future developments. Mini Reviews should be approximately 2000 words. The abstract should not exceed 300 words and should be str正文 ≤ 2,000 词
- original research articleView our topical sections currently accepting submissions View our Special Collections currently accepting submissions View our Author Resource page for guidanc…未说明篇幅
- original research articlesOriginal Research articles未说明篇幅
- perspectivemitted as an original research article. Perspectives Description: Perspectives are opinion pieces and should not exceed 3,000 words and 30 references. Perspecti…正文 ≤ 3,000 词
- research articleView our topical sections currently accepting submissions View our Special Collections currently accepting submissions View our Author Resource page for guidanc…未说明篇幅
- reviewView our topical sections currently accepting submissions View our Special Collections currently accepting submissions View our Author Resource page for guidanc…未说明篇幅
官网政策摘录作者资格、数据可用性、出版伦理、开放获取、同行评审、查重、预印本、试验注册 / 报告规范
- 作者资格 Author contributions
该期刊要求在投稿过程中列出每位作者的贡献，并在提交稿件的致谢部分之后包含“作者贡献”标题，所提供的信息将在校对阶段显示在“作者贡献”标题下。 模型中文摘要
You will be asked to list the contribution of each author as part of the submission process. Please include the Author Contributions heading within your submission after the Acknowledgements section. The information you give on submission will then show under the Author Contributions heading later at the proofing stage.
原文 ↗出版商官网 ·- 数据可用性 Data availability
该期刊致力于促进研究的开放性、透明度和可重复性，鼓励作者在符合伦理和法律要求的前提下，将研究数据共享到相关的公共数据存储库，并包含链接到数据的数据可用性声明；如果无法共享数据，则使用该声明确认原因，并在研究中引用这些数据。 模型中文摘要
The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…
原文 ↗出版商官网 ·- 出版伦理 Ethical considerations
该期刊要求在指定标题下包含伦理批准声明，即使已在方法部分包含伦理批准信息；如果不需要伦理批准，则必须明确说明；所有报告涉及人类参与者、人类数据或人体组织的研究的论文必须声明相关伦理委员会或机构审查委员会批准了该研究或豁免了批准要求，并提供审查委员会的全名、机构以及批准编号。 模型中文摘要
Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…
原文 ↗出版商官网 ·- 开放获取 Publishing fees and open access
该期刊为开放获取、同行评审期刊，所有被接受的文章在出版后立即免费在线提供，采用知识共享许可协议并永久在线托管；稿件经同行评审被接受后需支付一次性文章处理费（APC），由资助者、机构或作者支付，投稿不收费，该期刊的APC为3200美元，简报、评论和技术说明可享受标准APC 20%的折扣，社论无需支付APC。 模型中文摘要
Technology in Cancer Research & Treatment is an open access, peer-reviewed journal. All accepted articles are made freely available online immediately upon publication, are published under a Creative Commons license, and hosted online in perpetuity. If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable to cover the cost of publish…
原文 ↗出版商官网 ·- 同行评审 Peer review policy
该期刊采用双匿名同行评审流程，稿件将首先进行初步评估，不符合指南要求的稿件将在同行评审前退回修改，超出期刊范围或不适用的稿件可能会在此时被直接拒稿（desk reject）。 模型中文摘要
The following summary describes the peer review process for this journal: Identity transparency: Double-anonymized Reviewer interacts with: Executive Editor, Deputy Editor, Managing Editors, Associate Editors Review information published: Review reports (author opt in) Review reports (reviewer opt in) Author/editor communication Reviewer identities (reviewer opt in) Editor identities Your manuscri…
原文 ↗出版商官网 ·- 查重 Plagiarism
该期刊和Sage非常重视版权侵权、抄袭或其他违反出版最佳实践的行为，请阅读Sage关于抄袭的完整政策以及可能采取的措施。 模型中文摘要
The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.
原文 ↗出版商官网 ·- 预印本 Preprints
该期刊接受已在预印本服务器上发布的稿件，投稿时需在指定字段输入预印本DOI，建议在投稿时告知期刊编辑部已发布的预印本，且在同行评审期间不应在预印本服务器上发布更新版本的稿件。 模型中文摘要
The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…
原文 ↗出版商官网 ·- 试验注册 / 报告规范 Clinical trial registration
该期刊遵循ICMJE要求，临床试验必须在首个受试者入组时或之前在WHO认可的公共试验注册机构注册，作为考虑发表的条件，且试验注册机构名称、URL和注册号必须包含在摘要末尾。 模型中文摘要
The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- SAGE Publications Inc.
- 出版国家或地区
- UNITED STATES
- 出版语言
- English
- 出版周期
- Bimonthly
- 创刊年份
- 2002
- ISSN
- 1533-0346
- 电子版 ISSN
- 1533-0338
- 官方链接
- 期刊主页 ↗DOAJ
- 投稿系统 ↗出版商官网
- 作者指南 ↗DOAJ
- Aims & Scope ↗DOAJ
- 专刊 / 特刊征稿 ↗出版商官网
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗DOAJ
- 编委会 ↗DOAJ
- 查重政策 ↗DOAJ
常见问题
关于 Technology in Cancer Research & Treatment 的常见问题
Technology in Cancer Research & Treatment 是中科院几区期刊？
2025 年升级版分区表中，Technology in Cancer Research & Treatment 为医学 4区，小类 肿瘤学 4 区。2026 年新锐版分区表中为医学 3区。不同版本与大小类分区不能混用。
Technology in Cancer Research & Treatment 的影响因子是多少？
LetPub 汇总的最新公布影响因子为 2.79，CiteScore 为 5.2，h-index 为 86。
Technology in Cancer Research & Treatment 的审稿周期多长？
投稿社区反馈的平均审稿速度为约 2 个月，平均录用比例反馈为“约80%”；期刊官网公布的录用率为 19.8%。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Technology in Cancer Research & Treatment 的投稿格式要求是什么？
据期刊作者指南：摘要：≤ 300 词；参考文献格式：AMA 格式；稿件模板：提供 LaTeX 与 Word 模板；首次投稿格式：允许不按期刊格式排版（free format）；推荐审稿人：可选；Highlights：可选；图文摘要：可选；投稿信：必须提供。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Technology in Cancer Research & Treatment 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 574 位编委中，中国大陆 103 位（约 18%）；人数最多的国家是 美国（208 位）、中国（103 位）、意大利（46 位）。统计按编委会页面列出的机构国家计，仅供参考。
Technology in Cancer Research & Treatment 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Technology in Cancer Research & Treatment 被 SCIE、Scopus、DOAJ 收录。期刊官网自述还被 Web of Science、MEDLINE、PubMed 收录，该清单未与各数据库逐一核对。
Technology in Cancer Research & Treatment 是开放获取期刊吗？版面费多少？
Technology in Cancer Research & Treatment 为完全开放获取。APC 约 2,650 美元。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex、DOAJ；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-26 归档）。最近更新：。